Tislelizumab-induced fulminant type 1 diabetes mellitus (FT1D): A case report and literature review

Tislelizumab can induce FT1D, which presents acutely and can be fatal. This case underscores the critical need for vigilant and regular blood glucose monitoring in patients receiving immune checkpoint inhibitors. Enhanced patient education on the symptoms of hyperglycemia is essential to enable early detection and prompt intervention, thereby preventing severe complications such asDKA.